Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Multiple myeloma is a malignant disorder characterized by the proliferation of plasma cells. Much insight has been gained into the molecular pathways that lead to myeloma and indeed much more remains to be done. The understanding of these pathways is closely linked to their therapeutic implications and is stressed upon in the initial chapters. Recently, the introduction of newer agents such as bortezomib, lenalidomide, thalidomide, liposomal doxorubicin, etc. has led to a flurry of trials aimed at testing various combinations in order to improve survival. Higher response rates observed with these agents have led to their integration into induction therapies. The role of various new therapies vis a vis transplantation has also been examined. Recent advances in the management of plasmacytomas , renal dysfunction, dentistry as well as mobilization of stem cells in the context of myeloma have also found exclusive mention. Since brevity is the soul of wit our attempt has been to present before the reader a comprehensive yet brief text on this important subject.

Multiple myeloma. --- Kahler's disease --- Plasma cell myeloma --- B cells --- Monoclonal gammopathies --- Plasmacytoma --- Tumors --- Oncology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Multiple Myeloma (MM), the second most common blood cancer in adults, is a clonal plasma cell malignancy within the bone marrow characterized by osteolytic bone lesions, renal disease, and immunodeficiency. It is now well established that MM cell- induced disruption of the bone marrow homeostasis between the highly organized cellular and extracellular compartments supports MM cell proliferation, survival, migration, and drug resistance via activation of various signaling pathways. Based on this knowledge, the prototypic drugs thalidomide, bortezomib, and lenalidomide, which target both MM cell

Multiple myeloma --- Kahler's disease --- Plasma cell myeloma --- B cells --- Monoclonal gammopathies --- Plasmacytoma --- Treatment. --- Tumors

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Our understanding of multiple myeloma (MM) is growing at a formidable pace, particularly in terms of risk factors and potential drug targets. Minimal residual disease (MRD) negativity is set to become the new benchmark in treatment, and cytogenetic analysis is now paving the way for personalized therapies. This second edition of 'Fast Facts: Multiple Myeloma and Plasma Cell Dyscrasias' includes: - the new IMWG SLiM CRAB criteria - the latest advances in diagnostic tests and imaging - cytogenetics and genetic profiling - induction therapy prior to SCT - new lenalidomide- and bortezomib-based regimens - second-generation proteasome inhibitors, histone deacetylase inhibitors and monoclonal antibodies treatments. This Fast Facts handbook provides a comprehensive overview of MM and other plasma cell dyscrasias, from bench to bedside, presenting the pathogenesis, diagnosis and treatment in the context of daily clinical practice. Contents: • Epidemiology and etiology Predisposing conditions associated with MM • Pathophysiology of MM and MGUS • Diagnosis, staging and monitoring of multiple myeloma • Genetics and multiple myeloma • Treatment of newly diagnosed multiple myeloma • Stem cell transplantation in multiple myeloma • Relapsed and refractory multiple myeloma • Bone disease and renal complications • AL amyloidosis • Rare plasma cell dyscrasias • Supportive care

Multiple myeloma. --- Kahler's disease --- Plasma cell myeloma --- B cells --- Monoclonal gammopathies --- Plasmacytoma --- Tumors

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book is a comprehensive overview of the recent developments in the clinical and research fields of multiple myeloma. It is divided into three main sections that cover a wide range of topics, including: epidemiology and pathogenesis of the disease, genetic targets and pathways, resistance to novel therapies, angiogenesis and anti-angiogenesis, hematopoietic stem cell transplantation, role of radiology and radiotherapy in myeloma, infectious complications, and management of multiple myeloma in resource-poor countries.

Multiple myeloma. --- Kahler's disease --- Plasma cell myeloma --- B cells --- Monoclonal gammopathies --- Plasmacytoma --- Tumors --- Medicine --- Hematological Oncology --- Hematology --- Health Sciences

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Lymphomas --- Multiple myeloma --- Lymphoma. --- Multiple Myeloma. --- Lymphomas. --- Multiple myeloma. --- Kahler's disease --- Plasma cell myeloma --- Germinoblastomas --- Immunoblastomas --- Lymphoma --- Non-Hodgkin's lymphoma --- Reticulolymphosarcomas --- Sarcoma, Germinoblastic --- Sarcoma, Immunoblastic --- Kahler Disease --- Myeloma, Multiple --- Myeloma-Multiple --- Myelomatosis --- Plasma Cell Myeloma --- Myeloma, Plasma-Cell --- Cell Myeloma, Plasma --- Cell Myelomas, Plasma --- Disease, Kahler --- Multiple Myelomas --- Myeloma Multiple --- Myeloma, Plasma Cell --- Myeloma-Multiples --- Myelomas, Multiple --- Myelomas, Plasma Cell --- Myelomas, Plasma-Cell --- Myelomatoses --- Plasma Cell Myelomas --- Plasma-Cell Myeloma --- Plasma-Cell Myelomas --- Germinoblastoma --- Lymphoma, Malignant --- Reticulolymphosarcoma --- Germinoblastic Sarcoma --- Germinoblastic Sarcomas --- Lymphomas, Malignant --- Malignant Lymphoma --- Malignant Lymphomas --- Sarcomas, Germinoblastic --- Multiple Myeloma --- Myeloma Proteins --- Lymphatic Diseases --- Hematologic Neoplasms --- B cells --- Monoclonal gammopathies --- Plasmacytoma --- Lymphoproliferative disorders --- Reticulo-endothelial system --- Tumors